Cryoport; Sales of CAR-T Products Yescarta and Kymriah are In-line with My Projections (CYRX, Buy, $20.67)
Cryoport will report 2Q, 2019 results on August 8, 2019 at 5:00 PM EST. One area of keen interest for investors will be sales relating to the support of the CAR-T products-Gilead’s Yescarta and Novartis’ Kymriah. Gilead has reported that Yescarta sales in 2Q, 2019 were $120 million which compares to my last published estimate of $116 million. Sales of Novartis’ Kymriah were $58 million versus my estimate of $62 million. These results were effectively in-line with my estimates. For more detail on my Cryoport sales and EPS projections for 2Q, 2019 refer to my May 20 report Cryoport: Details of My Model for Sales for 2018 to 2024.
My sales projections for Yescarta and Kymriah are unchanged from the May 20 report and are as follows:
Tagged as CAR-T Products, Cryoport, Kymriah, Yescarta + Categorized as LinkedIn, Smith On Stocks Blog